drugset
drugset / Trial / NCT04857866

Safety, Tolerability and PK of a Single Subcutaneous Injection of XmAb27564 in Healthy Volunteers

NCT04857866 ↗

Phase 1 Completed 48 enrolled Xencor, Inc. ICON Clinical Research · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a Phase 1, randomized, double-blind, placebo-controlled, single ascending-dose study of subcutaneously administered XmAb27564 or placebo in healthy male and female subjects.

Timeline

Start
2021-04-19
Primary completion
2022-11-10
Completion
2022-11-10

Drugs

EvaluationDrugModalityDoseRoute
Subject XmAb27564 Protein / enzyme biologic — Subcutaneous

Indications

No indication recorded.